Merck recently announced its plans to lay off R&D workers at three East Coast sites; a move that will supposedly affect less than 10 percent of discovery, preclinical, and early development employees in Kenilworth and Rahway, N.J., and North Wales, PA. What I find interesting is that in the same Wall Street Journal article announcing the downsizing a spokesperson states that Merck is making the changes to have “earlier access to emerging external science and technology to augment our leading discovery and development capabilities.”
